Literature DB >> 28024656

Validation of Bleeding Classifications in Coronary Artery Bypass Grafting.

Debora Brascia1, Daniel Reichart2, Francesco Onorati3, Andrea Perrotti4, Vito G Ruggieri5, Karl Bounader5, Jean Philippe Verhoye5, Giuseppe Santarpino6, Theodor Fischlein6, Daniele Maselli7, Carmelo Dominici7, Giovanni Mariscalco8, Riccardo Gherli9, Antonino S Rubino10, Marisa De Feo11, Ciro Bancone11, Giuseppe Gatti12, Francesco Santini13, Magnus Dalén14, Matteo Saccocci15, Giuseppe Faggian3, Tuomas Tauriainen1, Eeva-Maija Kinnunen1, Francesco Nicolini16, Tiziano Gherli16, Stefano Rosato17, Fausto Biancari18.   

Abstract

Perioperative bleeding is a determinant of poor outcome in patients undergoing coronary artery bypass grafting (CABG), but there is a lack of adequate stratification of its severity. The ability of the European registry of Coronary Artery Bypass Grafting (E-CABG), Universal Definition of Perioperative Bleeding (UDPB), Study of Platelet Inhibition and Patient Outcomes (PLATO), Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7), Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events (ESSENCE), and SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation (STEEPLE) bleeding classifications to predict early mortality, stroke, acute kidney injury (AKI) stage 3, and deep sternal wound infection/mediastinitis was investigated in 3,730 patients from the prospective, multicentre E-CABG registry. Increasing grades of the E-CABG, UDPB, PLATO, and CURRENT-OASIS 7 classifications were associated with increasing risks of early mortality, had similar receiver-operating characteristic area under the curves (>0.7), and were predictive also when adjusted for EuroSCORE II. The E-CABG and UDPB classifications had satisfactory area under the curves (>0.6) in predicting stroke, AKI stage 3, and deep sternal wound infection/mediastinitis even when adjusted for EuroSCORE II. The PLATO and CURRENT-OASIS 7 classifications had similar predictive ability for stroke and AKI stage 3 as confirmed by multivariate analysis adjusted for EuroSCORE II but showed inferior ability in predicting severe wound infection compared to the E-CABG and UDPB classifications. The STEEPLE and ESSENCE classifications had a poor ability of predicting all these adverse events. Decision curve analysis showed a benefit of the E-CABG bleeding classification over the other classifications in predicting all adverse events. In conclusion, the E-CABG, UDPB, PLATO, and CURRENT-OASIS 7 bleeding classifications have a satisfactory ability in predicting adverse events after CABG. Decision curve analysis showed that the E-CABG bleeding classification had the best predictive performance.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28024656     DOI: 10.1016/j.amjcard.2016.11.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Preventing and managing catastrophic bleeding during extracorporeal circulation.

Authors:  Keyvan Karkouti; Loretta T S Ho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Impact of major bleeding on the risk of acute kidney injury in patients undergoing off-pump coronary artery bypass grafting.

Authors:  Wei Liu; Ziwei Xi; Chengxiong Gu; Ran Dong; Jumana AlHelal; Zhenxian Yan
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  The Prognostic Significance of Different Bleeding Classifications in off-pump coronary artery bypass grafting.

Authors:  Ziwei Xi; Yanan Gao; Zhenxian Yan; Yu-Jie Zhou; Wei Liu
Journal:  BMC Cardiovasc Disord       Date:  2020-01-10       Impact factor: 2.298

4.  Bleeding Classifications in CABG: perspective on Prognostic Performance.

Authors:  Rohan Magoon; Souvik Dey; Jasvinder Kaur Kohli; Ramesh Kashav
Journal:  Braz J Cardiovasc Surg       Date:  2020-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.